Insider Selling: Tempus AI, Inc. (NASDAQ:TEM) CEO Sells $190,363,747.50 in Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric P. Lefkofsky sold 3,240,234 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $58.75, for a total transaction of $190,363,747.50. Following the completion of the sale, the chief executive officer now owns 4,895,589 shares in the company, valued at $287,615,853.75. This represents a 39.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Tempus AI Stock Up 1.6 %

Shares of TEM opened at $56.18 on Friday. Tempus AI, Inc. has a twelve month low of $22.89 and a twelve month high of $91.45. The company has a 50 day moving average of $52.70 and a 200-day moving average of $52.46. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.

Hedge Funds Weigh In On Tempus AI

Hedge funds have recently made changes to their positions in the business. Operose Advisors LLC bought a new position in shares of Tempus AI during the 4th quarter worth approximately $25,000. First Horizon Advisors Inc. bought a new position in shares of Tempus AI during the 3rd quarter worth approximately $30,000. Farther Finance Advisors LLC bought a new position in shares of Tempus AI during the 4th quarter worth approximately $34,000. Prestige Wealth Management Group LLC grew its stake in shares of Tempus AI by 910.4% during the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock worth $36,000 after acquiring an additional 965 shares in the last quarter. Finally, NewEdge Advisors LLC bought a new position in shares of Tempus AI during the 4th quarter worth approximately $49,000. 24.22% of the stock is owned by institutional investors.

Analysts Set New Price Targets

TEM has been the topic of a number of analyst reports. Bank of America increased their price target on shares of Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research report on Friday, December 13th. Guggenheim reiterated a “buy” rating on shares of Tempus AI in a research report on Tuesday, February 25th. William Blair reiterated a “market perform” rating on shares of Tempus AI in a research report on Tuesday, February 25th. JPMorgan Chase & Co. downgraded shares of Tempus AI from an “overweight” rating to a “neutral” rating and increased their price target for the company from $50.00 to $55.00 in a research report on Tuesday, February 25th. Finally, TD Cowen reissued a “buy” rating and set a $74.00 target price (up from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. Six investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, Tempus AI currently has a consensus rating of “Moderate Buy” and an average price target of $60.55.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.